Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

ICARUS-IBD Working Group

doi:10.1053/j.gastro.2021.04.025

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

ICARUS-IBD Working Group

Research output: Contribution to journal › Short survey › peer-review

75 Scopus citations

Original language	English
Pages (from-to)	715-718.e4
Journal	Gastroenterology
Volume	161
Issue number	2
DOIs	https://doi.org/10.1053/j.gastro.2021.04.025
State	Published - Aug 2021

Access to Document

10.1053/j.gastro.2021.04.025

Cite this

@article{cbbf65b1911f4873bd8f1de123672c2c,

title = "Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies",

author = "{ICARUS-IBD Working Group} and Wong, {Serre Yu} and Rebekah Dixon and {Martinez Pazos}, Vicky and Sacha Gnjatic and Colombel, {Jean Frederic} and Ken Cadwell and Stephanie Gold and Drew Helmus and Neil, {Jessica Anne} and Stela Sota and Jang, {Kyung Ku} and Krystal Ching and Mericien Venzon and Xiaomin Yao and Lucie Bernard and Xin Chen and Reema Navalurkar and Michelle Mendiolaza and Pamela Reyes-Mercedes and Sara Nunez and Stephanie Stanley and Darwin Jimenez and Michael Tankelevich and Brianne Phillipe and Julio Ramos and Kevin Tuballes and Vanessa Barcessat and Natalia Herrera and Jack Satsangi and Kenji Watanabe and S{\'e}verine Vermeire and Flavio Steinwurz and Mark Silverberg and Rubin, {David T.} and Giulia Roda and Walter Reinisch and Ng, {Siew Chien} and James Lindsay and Jonas Halfvarson and Matthieu Allez and Vineet Ahuja and Maria Abreu",

note = "Funding Information: Conflicts of interest These authors disclose the following: Sacha Gnjatic receives research grants from Bristol-Myers Squibb, Genentech, Immune Design, Agenus, Janssen R&D, Pfizer, Takeda, and Regeneron and has advisory roles with Merck, Neon Therapeutics, and OncoMed. Jean-Frederic Colombel receives research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receives payment for lectures from AbbVie, Amgen, Allergan, Inc, Ferring Pharmaceuticals, Shire, and Takeda; receives consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Galxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, and Vifor; and holds stock options in Intestinal Biotech Development. Ken Cadwell receives research funding from Pfizer, Takeda, and Abbvie; has consulted for or received honorarium from Puretech Health, Genentech, and Abbvie; and holds US patent 10,722,600 and provisional patent 62/935,035. The remaining authors disclose no conflicts.Funding This work was supported by The Helmsley Charitable Trust and Cure for IBD. This effort was supported by the Serological Sciences Network (SeroNet) of the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003, and by grant UL1TR001433 from the National Center for Advancing Translational Sciences, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. Sacha Gnjatic was supported by National Institutes of Health grants CA224319 and DK124165. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.The authors thank The Mount Sinai Therapeutic Infusion Center team and Yamilka Costanza for their contributions to patient recruitment; Justin Conklin, Neil Birmingham, James Freeman, Don Chalfin, Ross Molinaro, and Kim Wilson from Siemens Healthineers for their support for serologic testing; Gustavo-Martinez-Delgado and Louis Cohen for laboratory support; Rohit Chandwani for assistance with statistical analysis; and Miriam Merad for valuable input on the study design. Serre-Yu Wong, MD, PhD (Conceptualization: Lead; Data curation: Equal; Formal analysis: Equal; Funding acquisition: Lead; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Lead; Visualization: Lead; Writing ? original draft: Lead; Writing ? review & editing: Equal). Rebekah Dixon, BS (Conceptualization: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Writing ? review & editing: Equal). Vicky Martinez Pazos, BS (Investigation: Equal; Methodology: Equal; Writing ? review & editing: Supporting). Sacha Gnjatic, PhD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Methodology: Equal; Visualization: Equal; Writing ? review & editing: Equal). Jean-Frederic Colombel, MD (Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Supporting; Writing ? review & editing: Equal). Ken Cadwell, PhD (Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Equal; Writing ? review & editing: Equal). Funding Information: Funding This work was supported by The Helmsley Charitable Trust and Cure for IBD. This effort was supported by the Serological Sciences Network (SeroNet) of the National Cancer Institute, National Institutes of Health , under Contract No. 75N91019D00024, Task Order No. 75N91020F00003, and by grant UL1TR001433 from the National Center for Advancing Translational Sciences , National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. Sacha Gnjatic was supported by National Institutes of Health grants CA224319 and DK124165. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai . The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. ",

year = "2021",

month = aug,

doi = "10.1053/j.gastro.2021.04.025",

language = "English",

volume = "161",

pages = "715--718.e4",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

AU - ICARUS-IBD Working Group

AU - Wong, Serre Yu

AU - Dixon, Rebekah

AU - Martinez Pazos, Vicky

AU - Gnjatic, Sacha

AU - Colombel, Jean Frederic

AU - Cadwell, Ken

AU - Gold, Stephanie

AU - Helmus, Drew

AU - Neil, Jessica Anne

AU - Sota, Stela

AU - Jang, Kyung Ku

AU - Ching, Krystal

AU - Venzon, Mericien

AU - Yao, Xiaomin

AU - Bernard, Lucie

AU - Chen, Xin

AU - Navalurkar, Reema

AU - Mendiolaza, Michelle

AU - Reyes-Mercedes, Pamela

AU - Nunez, Sara

AU - Stanley, Stephanie

AU - Jimenez, Darwin

AU - Tankelevich, Michael

AU - Phillipe, Brianne

AU - Ramos, Julio

AU - Tuballes, Kevin

AU - Barcessat, Vanessa

AU - Herrera, Natalia

AU - Satsangi, Jack

AU - Watanabe, Kenji

AU - Vermeire, Séverine

AU - Steinwurz, Flavio

AU - Silverberg, Mark

AU - Rubin, David T.

AU - Roda, Giulia

AU - Reinisch, Walter

AU - Ng, Siew Chien

AU - Lindsay, James

AU - Halfvarson, Jonas

AU - Allez, Matthieu

AU - Ahuja, Vineet

AU - Abreu, Maria

N1 - Funding Information: Conflicts of interest These authors disclose the following: Sacha Gnjatic receives research grants from Bristol-Myers Squibb, Genentech, Immune Design, Agenus, Janssen R&D, Pfizer, Takeda, and Regeneron and has advisory roles with Merck, Neon Therapeutics, and OncoMed. Jean-Frederic Colombel receives research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receives payment for lectures from AbbVie, Amgen, Allergan, Inc, Ferring Pharmaceuticals, Shire, and Takeda; receives consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Galxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, and Vifor; and holds stock options in Intestinal Biotech Development. Ken Cadwell receives research funding from Pfizer, Takeda, and Abbvie; has consulted for or received honorarium from Puretech Health, Genentech, and Abbvie; and holds US patent 10,722,600 and provisional patent 62/935,035. The remaining authors disclose no conflicts.Funding This work was supported by The Helmsley Charitable Trust and Cure for IBD. This effort was supported by the Serological Sciences Network (SeroNet) of the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003, and by grant UL1TR001433 from the National Center for Advancing Translational Sciences, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. Sacha Gnjatic was supported by National Institutes of Health grants CA224319 and DK124165. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.The authors thank The Mount Sinai Therapeutic Infusion Center team and Yamilka Costanza for their contributions to patient recruitment; Justin Conklin, Neil Birmingham, James Freeman, Don Chalfin, Ross Molinaro, and Kim Wilson from Siemens Healthineers for their support for serologic testing; Gustavo-Martinez-Delgado and Louis Cohen for laboratory support; Rohit Chandwani for assistance with statistical analysis; and Miriam Merad for valuable input on the study design. Serre-Yu Wong, MD, PhD (Conceptualization: Lead; Data curation: Equal; Formal analysis: Equal; Funding acquisition: Lead; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Lead; Visualization: Lead; Writing ? original draft: Lead; Writing ? review & editing: Equal). Rebekah Dixon, BS (Conceptualization: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Writing ? review & editing: Equal). Vicky Martinez Pazos, BS (Investigation: Equal; Methodology: Equal; Writing ? review & editing: Supporting). Sacha Gnjatic, PhD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Methodology: Equal; Visualization: Equal; Writing ? review & editing: Equal). Jean-Frederic Colombel, MD (Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Supporting; Writing ? review & editing: Equal). Ken Cadwell, PhD (Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Equal; Writing ? review & editing: Equal). Funding Information: Funding This work was supported by The Helmsley Charitable Trust and Cure for IBD. This effort was supported by the Serological Sciences Network (SeroNet) of the National Cancer Institute, National Institutes of Health , under Contract No. 75N91019D00024, Task Order No. 75N91020F00003, and by grant UL1TR001433 from the National Center for Advancing Translational Sciences , National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. Sacha Gnjatic was supported by National Institutes of Health grants CA224319 and DK124165. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai . The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85107647421&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.04.025

DO - 10.1053/j.gastro.2021.04.025

M3 - Short survey

C2 - 33887219

AN - SCOPUS:85107647421

SN - 0016-5085

VL - 161

SP - 715-718.e4

JO - Gastroenterology

JF - Gastroenterology

IS - 2

ER -